In Silico Study of the Selective Inhibition of Bacterial Peptide Deformylases by Several Drugs

Abdelouahab Chikhi* and Abderrahmane Bensegueni

Department of biochemistry-microbiology Faculty of natural and life sciences, Mentouri University, Constantine, Algeria

Abstract

To counter increasing levels of pathogen resistance new classes of antibiotics are needed without delay. The metalloenzyme peptide deformylase (PDF) correspond to one of the most promising bacterial targets in the search for novel mode of antibiotics action and was firstly selected as a specific bacterial target. Peptide analogs were developed as inhibitors containing a hydroxamate or formyl-hydroxylamine as metal interacting group, and used as inhibitors with in vitro activity against a broad spectrum of organisms and successful antibacterial activity in vivo that is harmonizing with good pharmacokinetic properties and excellent tolerability in diverse species, but a human homologue was recently discovered. A new strategy for selecting highly efficient compounds with low inhibition effect against human PDF was developed. An original class of small, non-peptidic inhibitors of peptide deformylase (PDF) as potent antibiotics such as indol-group and its derivatives with the same mode of action in vivo as previously identified PDF inhibitors but without the apoptotic effects of these inhibitors in human cells, has been discovered. This study has confirmed the selective action of these compounds on bacterial PDFs by docking method using the autodock program. Indeed, a good correlation between IC50 and deltaG values of different complexes PDF-inhibitors was observed. The evaluation of the various molecular properties of these inhibitors lets us conclude that all these compounds are most likely druggable.

Keywords: Antibiotics; Peptide deformylase; Human homologue; Docking; Autodock; molecular properties; Lipinski’s rule

Introduction

For a long time, it has been widely established that eukaryotes have no peptide deformylase (Mazel et al., 1994; Yuan et al., 2001). Since this enzyme is essential in bacteria and in several human parasites, peptide deformylase (PDF) was then acknowledged as an exceptional target for the design of new antibacterial (Yuan et al., 2001; Giglione et al., 2000; Pei, 2001) and antiparasitic agents (Meinnel et al., 2000).

Several studies of PDFs in complex with an inhibitor has given guidelines for the design of high affinity PDF inhibitors (Guilloteau et al., 2002; Hao et al., 1999). Actinin, a natural pseudopeptide hydroxamate compound and many of its derivatives have been shown to display powerful antibiotic activity (Chen et al., 2000; Gordon et al., 1962; Boularat et al., 2004; Chikhi et al., 2006). Phase I clinical studies were recently completed for two such potent peptide deformylase inhibitors derived from actinin (Ramanathan-Girish et al., 2004; Fritsche et al., 2005; Bush et al., 2004), which have now gone on to phase II and III trials.

Though recent studies have led to the identification of peptide deformylases in eukaryotes. These enzymes are targeted to the plastids and mitochondria of plants and to animal mitochondria (Giglione and Meinnel, 2001; Giglione et al., 2000). Two PDFs have been identified in plants and one in humans. Since they do not contain the two insertions typical of PDF2 molecules, all eukaryotic PDFs are without ambiguity of type 1 (PDF1). However, the amino acid sequence of the PDF specific to mitochondria differs from those of other PDF1s in some specific features. There are some changes in the proximity of the active site (Serero et al., 2003), PDF1 molecules therefore form two classes: PDF1A and PDF1B. PDF1Bs correspond to bacterial and plastid PDFs, whereas PDF1As correspond to mitochondrial PDFs. Unlike PDF1B, which is specific to plants, PDF1A is found in almost all eukaryotes. The PDF2 molecules belong exclusively to bacteria.

Likewise the process of deformylation has been shown to be an essential process in eukaryotes (Giglione et al., 2003; Lee et al., 2004). Unlike eukaryotic PDF1Bs, which do not differ significantly from bacterial PDFs in terms of their biochemistry (Serero et al., 2001) or three-dimensional structures (Kumar et al., 2002), PDF1As have a number of specific features.

Enzymatic studies have also shown that PDF1As from plants and animals differ from bacterial PDFs in a number of ways. These differences were investigated, and guidelines for the design of PDF-Inhibitors without anti-PDF1A activity were developed (Serero et al., 2003; Serero et al., 2001).

Docking plays an important role in the rational design of drugs (Kichen et al., 2004). Given the biological and pharmaceutical significance of molecular docking, considerable efforts have been directed towards improving the methods used to predict docking.

Effectively, several studies estimating and comparing the accuracies of protein-ligand programs like Autodock, ICM, Gold... have been reported (Perola et al., 2004; Bursulaya et al., 2003; Chikhi and Bensegueni, 2008). Autodock4.0 is a set of closely related programs and algorithms developed at the Scripps Research Institute. For a long time, it has been comparatively established that several PDFs inhibitor have no peptide deformylase (Mazel et al., 1994; Yuan et al., 2001). Since this enzyme is essential in bacteria and in several human parasites, peptide deformylase (PDF) was then acknowledged as an exceptional target for the design of new antibacterial (Yuan et al., 2001; Giglione et al., 2000; Pei, 2001) and antiparasitic agents (Meinnel et al., 2000).

Several studies of PDFs in complex with an inhibitor has given guidelines for the design of high affinity PDF inhibitors (Guilloteau et al., 2002; Hao et al., 1999). Actinin, a natural pseudopeptide hydroxamate compound and many of its derivatives have been shown to display powerful antibiotic activity (Chen et al., 2000; Gordon et al., 1962; Boularat et al., 2004; Chikhi et al., 2006). Phase I clinical studies were recently completed for two such potent peptide deformylase inhibitors derived from actinin (Ramanathan-Girish et al., 2004; Fritsche et al., 2005; Bush et al., 2004), which have now gone on to phase II and III trials.

Though recent studies have led to the identification of peptide deformylases in eukaryotes. These enzymes are targeted to the plastids and mitochondria of plants and to animal mitochondria (Giglione and Meinnel, 2001; Giglione et al., 2000). Two PDFs have been identified in plants and one in humans. Since they do not contain the two insertions typical of PDF2 molecules, all eukaryotic PDFs are without ambiguity of type 1 (PDF1). However, the amino acid sequence of the PDF specific to mitochondria differs from those of other PDF1s in some specific features. There are some changes in the proximity of the active site (Serero et al., 2003), PDF1 molecules therefore form two classes: PDF1A and PDF1B. PDF1Bs correspond to bacterial and plastid PDFs, whereas PDF1As correspond to mitochondrial PDFs. Unlike PDF1B, which is specific to plants, PDF1A is found in almost all eukaryotes. The PDF2 molecules belong exclusively to bacteria.

Likewise the process of deformylation has been shown to be an essential process in eukaryotes (Giglione et al., 2003; Lee et al., 2004). Unlike eukaryotic PDF1Bs, which do not differ significantly from bacterial PDFs in terms of their biochemistry (Serero et al., 2001) or three-dimensional structures (Kumar et al., 2002), PDF1As have a number of specific features.

Enzymatic studies have also shown that PDF1As from plants and animals differ from bacterial PDFs in a number of ways. These differences were investigated, and guidelines for the design of PDF-Inhibitors without anti-PDF1A activity were developed (Serero et al., 2003; Serero et al., 2001).

Docking plays an important role in the rational design of drugs (Kichen et al., 2004). Given the biological and pharmaceutical significance of molecular docking, considerable efforts have been directed towards improving the methods used to predict docking.

Effectively, several studies estimating and comparing the accuracies of protein-ligand programs like Autodock, ICM, Gold... have been reported (Perola et al., 2004; Bursulaya et al., 2003; Chikhi and Bensegueni, 2008). Autodock4.0 is a set of closely related programs and algorithms developed at the Scripps Research Institute.

*Corresponding author: Abdelouahab Chikhi, Department of biochemistry-microbiology Faculty of natural and life sciences, Mentouri University, Constantine, Algeria, Tel: + 213-793-112-547; E-mail: achikhi@yahoo.fr, achikhi@umc.edu.dz

Received December 29, 2009; Accepted February 13, 2010; Published February 15, 2010

Citation: Chikhi A, Bensegueni A (2010) In Silico Study of the Selective Inhibition of Bacterial Peptide Deformylases by Several Drugs. J Proteomics Bioinform 3: 061-065. doi:10.4172/jpb.1000122

Copyright: © 2010 Chikhi A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ISSN:0974-276X JPB, an open access journal
Research Institute and the University of California at San Diego. It was used in this study for the evaluation of the binding energies of the various complexes pdf-inhibitors.

The aim of this study was to check and then confirm by docking method the activity of new compounds that would selectively inhibit both types of bacterial PDFs (PDF1B and PDF2) without significantly inhibiting human PDF (PDF1A) and to estimate the drug-likeness of these new molecules by evaluation of the Lipinski’s Rule of Five.

Methods

AutoDock4.0 explores the conformational space of the ligand using the Lamarckian genetic algorithm (LGA), which is a hybrid of a genetic algorithm (GA) with an adaptive local search (LS) method (Morris et al., 1998). In this approach, the ligand’s state is represented as a chromosome, which is composed of a string of real-valued genes describing the ligand location (three coordinates), orientation (four quaternions) and conformation (one value for each torsion). The simulation is started by creating a random population of individuals. It is followed by a specified number of generation cycles, each consisting of the following steps: mapping and fitness evaluation, selection, crossover, mutation and elitist selection. Each generation cycle is followed by a local search. The solutions are scored using an energy-based scoring function, which includes terms accounting for short-ranged Van Der Waals and electrostatic interactions, loss of entropy upon ligand binding, hydrogen bonding and solvation.

AutoDock requires the receptor and ligand coordinates in MOL2 format. Nonpolar hydrogen atoms were removed from the receptor file and their partial charges were added to the corresponding carbon atoms. The program Mol2topdbqs was used to transform the receptor MOL2 file into the PDBQS format file containing the receptor atom coordinates, partial charges and solvation parameters. The program AutoTors was used to transform the ligand MOL2 file into a PDBQ file, merge nonpolar hydrogen atoms and define torsions. The grid calculations were set up with the utility Mkgpf3 and maps were calculated with the program AutoGrid. The grid maps were centered on the ligand’s binding site and were of dimension 61 × 61 × 61 points. The grid spacing was 0.375 Å yielding a receptor model that included short-ranged Van Der Waals and electrostatic interactions, loss of entropy upon ligand binding, hydrogen bonding and solvation.

AutoDock requires the receptor and ligand coordinates in MOL2 format. Nonpolar hydrogen atoms were removed from the receptor file and their partial charges were added to the corresponding carbon atoms. The program Mol2topdbqs was used to transform the receptor MOL2 file into the PDBQS format file containing the receptor atom coordinates, partial charges and solvation parameters. The program AutoTors was used to transform the ligand MOL2 file into a PDBQ file, merge nonpolar hydrogen atoms and define torsions. The grid calculations were set up with the utility Mkgpf3 and maps were calculated with the program AutoGrid. The grid maps were centered on the ligand’s binding site and were of dimension 61 × 61 × 61 points. The grid spacing was 0.375 Å yielding a receptor model that included short-ranged Van Der Waals and electrostatic interactions, loss of entropy upon ligand binding, hydrogen bonding and solvation.

All results are gathered in the following figures. The Figure 2, Figure 3 and Figure 4 show the relationship between IC50 and DeltaG values of diverses complexes PDF-inhibitors. A good correlation was observed between IC50 and DeltaG values for both bacterial PDFs (PDF1B and PDF2) and plant AtPDF1B with r=0.83, r=0.90 and r=0.84 respectively. Interesting interactions were detected between PDF1B, PDF2, AtPDF1B and diverses inhibitors with sufficiently high DeltaG values especially for three compounds 6b, 6d and 16 with -38.1, -42.0 and -40.02 Kj/mol respectively.

The interactions between one of the best inhibitors (compound 6b) and diverses PDFs are represented in the following Figures.

On a total of six H-bonds, two amino acids act as H-bonds donors among which two are realized by NH of Leu91 and one by NE2 of Gln50 with O12 of 6b compound. Others take place between atoms of three amino acids His132 (NE2), Glu133 (OE2) and

![Figure 1: Structure formulas of the twelve inhibitors.](image_url)

![Figure 2: Relationship among IC50 and DeltaG values of diverses complexes PDF1B-Inhibitors.](image_url)
and His136 (NE2) who intervene as H-bonds acceptors and OH14, NH13, and OH14 of 6b compound respectively.

Over the 5 H-bonds, three are made by OE1 and OE2 atoms of the same amino acid Glu133 which acts as H-bonds acceptor with NH13 and OH14 of 6b compound while two others are realized by NH of Leu91 and NE2 of Gln50 who react as H-bonds donors with O12 of 6b compound.

The docking’s results denote that the indol group and its derivatives act on the various bacterial PDFs (Figure 5 and Figure 6) but not on the human PDF (Figure 7).

Lipinski’s Rule of Five is a rule of thumb to evaluate drug-likeness, or determine if a chemical compound with a certain pharmacological or biological activity has properties that would make it a likely orally active drug in humans. The rule was formulated by Christopher A Lipinski (Lipinski et al., 1997).

The rule describes molecular properties important for a drug’s pharmacokinetics in the human body, including their absorption, distribution, metabolism, and excretion (“ADME”). The rule is important for drug development where a pharmacologically active lead structure is optimized step-wise for increased activity and selectivity, as well as drug-like properties as described by Lipinski’s rule.

Lipinski’s Rule of Five states that, in general, an orally active drug has:

- Not more than 5 hydrogen bond donors (OH and NH groups)
- Not more than 10 hydrogen bond acceptors (notably N and O)
- Not more than 15 rotatable bonds (rotb)
- A molecular weight (M.W) under 500 g/mol
The compounds and that these molecules are accepted to be orally bioavailable.

A partition coefficient log P (mi.LogP) less than 5 Molinspiration cheminformatics package was used for the determination of the inhibitors’ molecular properties.

These results show that the Lipinski’s rule is respected for all the compounds and that these molecules are accepted to be orally bioavailable.

Conclusion

This theoretical study confirms clearly the experimental results and shows that autodock program can be used to predict enzyme-inhibitors’ interactions. Our results prove that the inhibitors’ molecular properties.

Molecular properties of the inhibitors.

| Compounds | n.atoms | M.W   | n.O,N | n.OH,NH | n.rot.b | mi.LogP |
|-----------|---------|-------|-------|---------|---------|---------|
| 6a        | 14      | 190.202 | 4     | 3       | 2       | 1.056   |
| 6b        | 15      | 269.098 | 4     | 3       | 2       | 1.841   |
| 6d        | 25      | 403.232 | 6     | 2       | 5       | 3.353   |
| 6e        | 15      | 208.192 | 4     | 3       | 2       | 1.172   |
| 6f        | 15      | 208.192 | 4     | 3       | 2       | 0.222   |
| 6g        | 15      | 224.647 | 4     | 3       | 2       | 1.710   |
| 6h        | 16      | 220.228 | 5     | 3       | 3       | 1.089   |
| 6i        | 15      | 269.098 | 4     | 3       | 2       | 1.841   |
| 6j        | 16      | 283.125 | 4     | 3       | 2       | 2.063   |
| 11        | 14      | 255.115 | 3     | 3       | 2       | 2.336   |
| 15        | 22      | 364.219 | 5     | 3       | 3       | 3.861   |
| 16        | 24      | 392.229 | 6     | 2       | 3       | 3.489   |

Table 1: Molecular properties of the inhibitors.

Acknowledgements

The authors would like to thank Pr David Perahia for the AutoDock 4.0 academic license.

References

1. Boularot A, Giglione C, Artaud I, Meinnel T (2004) Structure-activity relationship and Therapeutic potential of peptide deformylase inhibitors Curr Opin Invest Drugs 5: 809-822. » CrossRef » PubMed » Google Scholar
2. Boularot A, Giglione C, Petit S, Duruc Y, Alves de Sousa R, et al. (2007) Discovery and refinement of a new structural class of potent peptide deformylase inhibitors J. Med. Chem 50: 10-20. » CrossRef » PubMed » Google Scholar
3. Bursulaya BD, Tootov M, Abagyan R, Brooks CL 3rd (2003) Comparative study of several algorithms for flexible ligand docking. J Comput Aided Mol Des 17: 755-763. » CrossRef » PubMed » Google Scholar
4. Bush K, Macielag M, Weidner-Wells M (2004) Taking inventory: antibacterial agents currently at or beyond phase I. Curr Opin Microbiol 7: 466-476. » CrossRef » PubMed » Google Scholar
5. Chen DZ, PatelDV, Hackbarth CJ, Wang W, Dreyer G, et al. (2000) Actinomycin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry 39: 1256-1262. » CrossRef » PubMed » Google Scholar
6. Chikhi A, Bensegueni A (2008) Comparative Study of the Efficiency of Three Protein-Ligand Docking Programs. J Proteomics Bioinform 1: 161-165. » CrossRef » PubMed » Google Scholar
7. Chikhi A, Bensegueni A, Boulalrof A Bencharif M (2006). Theoretical study of Escherichia coli peptide deformylase inhibition by several drugs In Silico Biology 6: 459-466. » CrossRef » PubMed » Google Scholar
8. Fritsche TR, Sader HS, Cleeeland R, Jones RN (2005) Comparative Antimicrobial Characterization of LBM415 (NVP-PDF113), a New Peptide Deformylase Inhibitor of Clinical Importance Antimicrob. Agents Chemother 49: 1468-1476. » CrossRef » PubMed » Google Scholar
9. Giglione C, Meinnel T (2001) Organellar peptide deformylases: universality of the N-terminal methionine cleavage mechanism. Trends Plant Sci 6: 566-572. » CrossRef » PubMed » Google Scholar
10.Giglione C, Pierre M, Meinnel T (2000) Peptide deformylase as a target for new generation, wide-spectrum antibiotic agents. Mol Microbiol 36: 1197-1205. » CrossRef » PubMed » Google Scholar
11.Giglione C, Serero A, Pierre M, Boisson B, Meinnel T (2000) Identification of eukaryotic peptide deformylases reveals universality of N-terminal protein processing mechanisms. EMBO J 19: 5916-5929. » CrossRef » PubMed » Google Scholar
12.Gordon JJ, Kelly BK, Miller GA (1962) Actinomycin: an Antibiotic Substance produced by an Actinomycete Nature 195: 701-702. » CrossRef » PubMed » Google Scholar
13.Guilhouette JP, Mathieu M, Giglione C, Blanc V, Dupuy A, et al. (2002) The crystal structures of four peptide deformylases bound to the antibiotic actinomycin reveal two distinct types: a platform for the structure-based design of antibacterial agents J Mol Biol 320 : 951-962. » CrossRef » PubMed » Google Scholar
14.Giglione C, Vallon O, Meinnel T (2003) Control of protein life-span by N-terminal methionine excision EMBO J 22: 13-23. » CrossRef » PubMed » Google Scholar
15.Hao B, Gong W, Rajagopalan PT, Zhou Y, Pei D, et al. (1999) Structural basis for the design of antibiotics targeting peptide deformylase. Biochemistry 38: 4712-4719. » CrossRef » PubMed » Google Scholar
16.Kitchen DB, Decornez H, Furr JR, Bajorath J (2004) Docking and scoring in virtual screening for drug discovery: methods and applications Nature reviews. Drug discovery 3: 950-954. » CrossRef » PubMed » Google Scholar
17.Kumar A, Nguyen KT, Sriwathsan S, Ornstein B, Turley S, et al. (2002) Crystals of peptide deformylase from Plasmodium falciparum reveal critical characteristics of the active site for drug design. Structure 10: 357-367. » CrossRef » PubMed » Google Scholar
18.Lee MD, She Y, Soskis MJ, Borella CP, Gardner JR, et al. (2004) Human mitochondrial peptide deformylase, a new anticancer target of actinomycin-based antibiotics. J Clin Invest 114: 1107-1116. » CrossRef » PubMed » Google Scholar
19. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Del Rev 23: 3-25. » CrossRef » PubMed » Google Scholar

20. Mazel D, Pochet S, Marliere P (1994) Genetic characterization of polypeptide deformylase, a distinctive enzyme of eubacterial translation. EMBO J 13: 914-923. » CrossRef » PubMed » Google Scholar

21. Meinnel T (2000) Peptide deformylase of eukaryotic protists: A target for new antiparasitic agents? Parasitol Today 16: 165-168. » CrossRef » PubMed » Google Scholar

22. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, et al. (1998) Automated Docking Using a Lamarckian Genetic Algorithm and and Empirical Binding Free Energy Function J Comput Chem 19: 1639-1662. » CrossRef » PubMed » Google Scholar

23. Pei D (2001) Peptide deformylase: a target for novel antibiotics? Emerg Ther Targets 5: 23-40. » CrossRef » PubMed » Google Scholar

24. Perola E, Walters WP, Charifson PS (2004) A detailed comparison of current docking and scoring methods on systems of pharmaceutical relevance. Proteins 56: 235-249. » CrossRef » PubMed » Google Scholar

25. Ramanathan-Girish S, McColm J, Clements JM, Taupin P, Barrowcliffe S, et al. (2004) Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor. Antimicrob Agents Chemother 48: 4835-4842. » CrossRef » PubMed » Google Scholar

26. Serero A, Giglione C, Meinnel T (2001) Distinctive features of the two classes of eukaryotic peptide deformylases. J Mol Biol 314: 695-708. » CrossRef » PubMed » Google Scholar

27. Serero A, Giglione C, Sardini A, Martinez Sanz J, Meinnel T (2003) An unusual peptide deformylase features in the human mitochondrial N-terminal methionine excision pathway J Biol Chem 278: 52953-52963. » CrossRef » PubMed » Google Scholar

28. Yuan Z, Trias J, White RJ (2001) Deformylase as a novel antibacterial target. Drug Discovery Today 6: 954-961. » CrossRef » PubMed » Google Scholar